Operates as a global Contract Research, Development and Manufacturing Organization (CRDMO), providing outsourced research, development and manufacturing services to pharmaceutical and biotechnology companies. Works with around 400 global customers and runs a workforce of over 8,300 employees. The business spans small-molecule CDMO work and a large-molecule / biologics CDMO (LMCDMO) franchise, supported by a material subsidiary, Syngene Scientific Solutions Limited, and the recently strengthened Syn.AI platform. FY26 revenue stood at Rs 3,738.7 crore with an EBITDA margin of 24.4%, but Q1 FY27 revenue fell 16% year-on-year to Rs 736 crore and EBITDA margin compressed to 12%, driven by lower offtake from a major biologics client and forex hedge losses. Employee costs are the largest expense at 29.6% of revenue, followed by materials at 24.4%, other operating expenses at 21.3% and depreciation at 12.1%, with capex running at 9.2% of revenue. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Small-molecule CDMO services, Large-molecule / biologics CDMO (LMCDMO). Asset-heavy contract research, development and manufacturing services with a large scientific workforce
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 2,604 | 3,193 | 3,489 | 3,642 | 3,739 |
| EBITDA (ex other income) | 765 | 934 | 1,003 | 1,074 | 842 |
| margin % | 29.4 | 29.3 | 28.8 | 29.5 | 22.5 |
| Owners' profit | 0 | 0 | 510 | 0 | 0 |
| EPS, as reported (₹) | 9.94 | 11.59 | 12.71 | 12.35 | 7.87 |
| ROE % · ROCE % | 12.0 · 11.7 | 12.8 · 13.8 | 12.0 · 13.3 | 10.5 · 13.2 | 6.5 · 8.4 |
| Debt / equity (x) | 0.24 | 0.16 | 0.03 | 0.03 | 0.00 |
| Cash from operations | 581 | 824 | 1,042 | 1,168 | 915 |
| Capex | (475) | (507) | (492) | (760) | (344) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 891 | 944 | 1,018 | 875 | 911 | 917 | 1,037 | 736 |
| Profit before tax | 137 | 181 | 241 | 101 | 85 | 28 | 196 | (19) |
| Net profit | 106 | 131 | 183 | 87 | 67 | 15 | 148 | (9) |
| EPS (₹) | 2.64 | 3.27 | 4.56 | 2.16 | 1.67 | 0.37 | 3.68 | (0.22) |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SYNGENE INTERNATIONAL LTD ◆ | 15,466 | 69.7 | 3.20 | 16.7 | 6.5 | 7.5 | 11.3 | 13.9 |
| INDEGENE LIMITED | 13,959 | 34.7 | 4.45 | 20.4 | 12.8 | 14.9 | — | 19.1 |
| SUVEN LIFE SCIENCES LTD | 9,476 | — | 16.02 | — | (46.7) | (46.6) | (12.0) | (3504.9) |
| VIMTA LABS LIMITED | 2,819 | 22.8 | 8.22 | 31.1 | 8.0 | 11.0 | 8.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · Syngene to meet True Beacon PMS on Sept 17 | board shareholder meetings | low | — | — |
| 10 Sept 2026 · Syngene remits final dividend of Rs 1.25/share for FY 2025-26 | corporate actions | high | — | — |
| 1 Sept 2026 · Syngene grants 14.26 lakh Performance Share Units to employees | capital market events | medium | — | — |
| 25 Aug 2026 · Analyst or investor meeting scheduled with Goldman Sachs Asia Leaders Conference | board shareholder meetings | low | — | — |
| 24 Aug 2026 · Syngene invests in Ampin C&I Power for renewable energy | strategic transactions | medium | — | — |
| 24 Aug 2026 · Syngene to meet Entrust Family Office on August 28 | board shareholder meetings | low | — | — |
| 10 Aug 2026 · Syngene to meet analysts at Emkay Confluence 2026 on Aug 13-14 | board shareholder meetings | low | — | — |
| 6 Aug 2026 · Q1 FY2027 earnings call transcript uploaded on website | investor communications | medium | — | — |
| 31 Jul 2026 · Syngene AGM 2026: All 9 resolutions approved, Rs 1.25 dividend cleared | board shareholder meetings | low | — | — |
| 30 Jul 2026 · Audio recording of Q1 FY27 earnings call shared | investor communications | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 38.2 |
| TAKE LIMITED | 261 | 20.5 | 8.40 | 54.5 | 35.0 | 14.2 | (41.2) | 3.5 |
| BILCARE LTD. | 219 | 6.2 | 2.95 | 11.8 | (23.3) | (3.9) | 3.3 | 15.7 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 69.7 | 31.2 | 58 of 68 | 15% |
| P/B | 3.2 | 5.2 | 23 of 57 | 61% |
| ROCE | 7.5 | 8.0 | 37 of 69 | 47% |
| ROE | 6.5 | 9.4 | 38 of 59 | 36% |
| Debt / Equity | 0.0 | 0.1 | 17 of 59 | 72% |
| EBITDA margin | 13.9 | 21.5 | 45 of 57 | 21% |
| Revenue growth | (15.8) | 20.2 | 50 of 57 | 13% |
| Profit growth | (110.4) | 11.4 | 50 of 55 | 9% |
| Market cap | 15466 | 261 | 10 of 71 | 87% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
